Targeting effector memory T-cells with Kv1.3 blockers

Heike Wulff, M. Pennington

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


After initially being pursued for general immunosuppression, the voltage-gated potassium channel Kv1.3 has more recently emerged as an attractive pharmacological target for the selective suppression of CCR7- effector memory T-cells in T-cell mediated autoimmune diseases such as multiple sclerosis, type 1 diabetes, rheumatoid arthritis and psoriasis. This article gives a brief summary of the role of Kv1.3 in autoimmune diseases, reviews the progress made in both developing peptidic and small-molecule inhibitors for this challenging target, and in validating Kv1.3 as a target for the treatment of autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)438-445
Number of pages8
JournalCurrent Opinion in Drug Discovery and Development
Issue number4
StatePublished - Jul 2007


  • Autoimmune disease
  • Effector memory T-cell
  • Immunosuppression
  • Kv1.3
  • Multiple sclerosis
  • Peptide toxin
  • Psoriasis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Targeting effector memory T-cells with Kv1.3 blockers'. Together they form a unique fingerprint.

Cite this